Business Wire

ATRC

12.2.2024 15:12:30 CET | Business Wire | Press release

Share
UAE's ATRC Launches Global Tech R&D Platform at WGS 2024: Allocates US$200 Mn Fund to Accelerate Innovation for Developing Nations

In a landmark announcement on Day 1 of the World Governments Summit (WGS) 2024, Abu Dhabi’s Advanced Technology Research Council (ATRC) unveiled a pioneering initiative aimed at facilitating global access to cutting-edge technology solutions. The newly launched ‘ATRC Global Tech R&D Platform’ serves as a channel for countries worldwide to tap into the UAE's technological expertise to address their unique challenges.

As the driving force behind Abu Dhabi and the wider UAE's advanced research and development (R&D) ecosystem, this initiative underscores ATRC's commitment to fostering inclusive growth and global prosperity. In an era of rapid technological transformation, the platform seeks to bridge technology gaps experienced by nations worldwide by offering tailored solutions to their pressing needs.

To initiate applications through the platform, ATRC is allocating US$200 million in funding to accelerate innovation, particularly for emerging and developing nations. By committing to absorb resource and research costs, the funding facilitates the development of sophisticated technology solutions, empowering these nations to keep pace with the latest advancements.

The ATRC Global Tech R&D Platform invites applications from governments, organizations, and eligible stakeholders all over the world, prioritizing collaboration, and inclusivity. Through a rigorous evaluation process, initiatives aligned with the platform's mission will receive support in six priority sectors: Aerospace and Space; Food and Agriculture; Healthcare; Safety and Security; Sustainability, Environment, and Energy; and Transport.

H.E. Faisal Al Bannai, Secretary General of ATRC, underscores the profound global impact of the initiative, stating: "Our commitment is to empower every nation with the means to thrive in this technology-driven world. ATRC stands ready to partner with countries worldwide, leveraging our expertise in technology to address their challenges and drive collective progress in the AI-driven era."

Over the span of almost four years, ATRC has developed a robust R&D ecosystem, with over 850 researchers from more than 70 countries. It has built an entire ecosystem that systematically supports every critical stage of a technology’s development journey. Its entity ASPIRE crowdsources global talent through grand challenges and global competitions and identifies technology gaps with its clients. The Technology Innovation Institute (TII) is focused on applied research with intentional outcomes and houses its leading researchers and scientists, while VentureOne commercializes its solutions, taking R&D products and services from lab to market.

ATRC offers a spectrum of capabilities spanning quantum and AI, autonomous robotics, and cryptography, as well as advanced materials, propulsion, and space – guiding technology needs from ideation to innovation.

From identifying an entity’s tech pain point to developing bespoke R&D solutions, ATRC orchestrates the complete lifecycle of technology advancement for companies and countries that need support. Situated at the global crossroads, it extends its reach to entities worldwide, facilitating innovation on a truly global scale.

Al Bannai is set to address a plenary session at the World Governments Summit, highlighting his views on AI’s evolution and emerging opportunities.

Dr. Ray O. Johnson, CEO of ATRC’s global applied research arm, TII, expressed optimism about the fund's potential to catalyze innovation, and said: "Through this platform, we will help identify untapped innovation around the world, unleashing the power of transformative technologies, and sparking economic growth."

ATRC is calling on nations to collaborate and contribute to the global technological landscape. For further details on the ATRC Tech R&D Fund, applicants can contact the Council via ASPIRE, at aspireuae.ae.

“We’re here to identify technology gaps and facilitate sophisticated solutions that countries may need to explore for a resilient future”, said Stephane Timpano, CEO of ASPIRE.

In a similar stance to support the wider adoption of advanced technologies, last year, the Technology Innovation Institute (TII) was among the first to open-source its world ranking large language model, Falcon 40B under the Apache 2.0 license – royalty-free.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212472252/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye